Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  enzalutamide
Find trials that include:  Any drugs shown
Results 1-25 of 34 for your search:
Start Over
A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
Phase: Phase IV
Type: Supportive care
Age: Not specified
Trial IDs: 9785-CL-0403, NCI-2014-01193, 2013-003022-92, U1111-1157-0224, NCT01977651
Enzalutamide with or without Abiraterone Acetate and Prednisone in Treating Patients with Castration-Resistant Metastatic Prostate Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A031201, NCI-2013-01737, CALGB-A031201, NCT01949337
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-14, NCI-2013-02393, NCT02003924
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-13, NCI-2015-00824, NCT02319837
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ARMOR3-SV, NCI-2015-00996, NCT02438007
Enzalutamide and Mifepristone in Treating Patients with Metastatic Hormone Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: IRB13-0979, NCI-2013-02151, CDMRP-PC121149, NCT02012296
Enzalutamide with or without Vaccine Therapy in Treating Patients with Metastatic Hormone Resistant Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-C-0146, NCI-2013-01565, 1301-1204, 130146, P121106, RD-13-I-11, NCT01867333
Enzalutamide with or without Vaccine Therapy in Treating Patients with Non-metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-C-0153, NCI-2013-01570, 1301-1205, 130153, P121105, RD-13-I-12, NCT01875250
Tivozanib and Enzalutamide in Treating Patients with Hormone Resistant Prostate Cancer That is Metastatic or Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-073, NCI-2013-01824, NCT01885949
Enzalutamide in Treating Patients with Metastatic, Castrate-Resistant Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-301, NCI-2013-02258, NCT01942837
Enzalutamide in Treating Patients with Advanced or Recurrent Androgen Receptor-Positive Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-119, NCI-2013-02217, NCT01974765
Enzalutamide and External Beam Radiation Therapy in Treating Patients with Intermediate Risk Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-444, NCI-2014-00951, NCT02028988
Androgen Deprivation Therapy, Enzalutamide, and Radiation Therapy in Treating Patients with Recurrent Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00049865, NCI-2014-01161, DUMC Pro00049865, NCT02057939
LHRH Analogue Therapy with Enzalutamide or Bicalutamide in Treating Patients with Metastatic Hormone Sensitive Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-083, NCI-2014-00212, 1311012529, NCT02058706
Enzalutamide and Leuprolide Acetate before, during, and after Radiation Therapy in Treating Patients with High-Risk Localized or Locally Advanced Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 to 90
Trial IDs: SCCC-16813, NCI-2014-02533, 082013-032, 8843, Mod5_STU 082013-032, NCI-2014-02510, NCT02064582
Testosterone Therapy Followed by Enzalutamide or Abiraterone Acetate in Treating Patients with Prostate Cancer That Is Progressing on Combined Androgen Therapies
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J1416, NCI-2014-01366, CIR00006889, CIR00011018, NA_00093344, NA_00093344 / CIR00011018, NCT02090114
Radium Ra 223 Dichloride and Enzalutamide in Treating Patients with Metastatic Prostate Cancer That Is Resistant to Antihormone Therapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: HCI68770, NCI-2014-01823, NCT02199197
Salvage Radiation Therapy with or without Enzalutamide in Treating Patients with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J1454, NCI-2015-00621, c14-138, CIR00007200, IRB00030471 / CIR00007200, NCT02203695
Enzalutamide versus Standard Androgen Deprivation Therapy in Reducing Incidence of Metabolic Syndrome in Patients with Advanced Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 19 and over
Trial IDs: 14-0909, NCI-2014-02219, NCT02278185
Testosterone Therapy or Enzalutamide in Treating Patients with Asymptomatic Hormone Resistant Metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J14146, NCI-2015-00158, CIR00007000, NA_00046414, NCT02286921
Start Over